Picture loading failed.

Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-094-1mg 1mg 3090
GMP-Bios-ab-094-10mg 10mg 21890
GMP-Bios-ab-094-100mg 100mg 148000
GMP-Bios-ab-094-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CCL2 therapeutic antibody (Pre-made Carlumab biosimilar,Whole mAb)
INN Name Carlumab
TargetCCL2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure4dn3:HL/4dn4:HL
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesMorphoSys;Janssen Biotech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedIdiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours
Development TechHuman Phage Display